Gregory Gosch, Founder, President and CEO
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields.  He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer's disease.  Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad.  He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.

Aditya Rajagopal, PhD, Founder and CTO
Aditya is the inventor of HDPCR, ChromaCode's core technology.  Most recently, he was a researcher with the Life Science team at Google[x], where he was exploring fundamentally transformative, "moonshot" endeavors. Aditya has 29 issued patents, 21 pending patents , and multiple publications in biomedical technology, microfluidics and nanotechnology. He has expertise in thermal engineering, signal processing techniques, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications. He was the recipient of the Caltech Innovation Initiative (CI2) award and the Demetriades-Tsafka-Kokkalis thesis prize. Additionally, he has an appointment as a Visiting Associate (Visiting Faculty) at Caltech. Aditya completed his education at Caltech (BS, MS, PhD), and performed his doctoral research with Dr. Axel Scherer and Dr. Tom Tombrello.. 

Karen Menge, PhD, Vice President of Research and Development

Karen has over 20 years industry experience in leadership capacities spanning research, product development, clinical affairs, regulatory, quality assurance, and operations. Her core expertise lies in the development and deployment of Molecular Diagnostic products. Most recently as Director of Programs for GSSHealth she was responsible for establishing programs for quality improvement in clinical laboratories serving HIV patients in West Africa, and prior to that was Associate Director of Development for the Novartis Dx Infectious Diseases Franchise. Karen earned her PhD in Biochemistry at the Johns Hopkins University School of Public Health and her Bachelor of Science in Biochemistry at the University of California Davis.

Lynne Rollins, CFO
Lynne has over 35 years’ experience in the healthcare industry in the areas of finance and business development. She is currently a CFO consultant for start-up pharmaceutical and medical device companies and has worked with 35 start-up companies over the last 15 years.  Prior to that, she was with Baxter Healthcare Corporation for 19 years. Her positions at Baxter included Vice President of Business Development for the Cardiopulmonary Business of the CardioVascular Group and Vice President of Finance for the Cardiopulmonary Business.  Ms. Rollins received her B.S. degree from California State University, Northridge and her MBA from Pepperdine University.  


Yaser S. Abu-Mostafa, PhD

Yaser is a Professor of Electrical Engineering and Computer Science at the California Institute of Technology, and Chairman of Machine Learning Consultants LLC. His main fields of expertise are machine learning and computational finance. He is the author of Amazon's machine learning bestseller Learning from Data. His MOOC on machine learning has attracted more than two million views.

He received the Clauser Prize for the most original doctoral thesis at Caltech. He received the ASCIT Teaching Awards in 1986, 1989 and 1991, the GSC Teaching Awards in 1995 and 2002, and the Richard P. Feynman prize for excellence in teaching in 1996. He was the founding Program Chairman of the annual conference on Neural Information Processing Systems (NIPS), and a founding member of the IEEE Neural Networks Council. He chaired the second and fourth international conferences on Neural Networks in the Capital Markets (NNCM-94 and NNCM-96), and the sixth international conference on Computational Finance (CF-99). In 2005, the Hertz Foundation established a perpetual graduate fellowship named in his honor.

Yaser currently serves as an advisor and technical consultant on machine learning for several companies, including Citibank for 9 years. He has numerous technical publications including 3 articles in Scientific American, as well as several keynote lectures at international conferences.

Gregory Tsongalis, PhD

Greg is the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center in Lebanon, NH and a Professor of Pathology at the Geisel School of Medicine at Dartmouth in Hanover, NH. He was the inaugural director of the molecular pathology laboratory at Hartford Hospital in Hartford, CT before going to Dartmouth. His area of expertise is in clinical molecular diagnostic applications. His research interests are in the pathogenesis of human cancers, personalized medicine and disruptive technologies. He has authored/edited eight textbooks in the field of molecular pathology, published more than 185 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings.

Greg has served on numerous committees of the AACC, ASIP, and AMP where he is a past President and currently serves on the FASEB board of directors. He is on the editorial board of 9 journals including Clinical Chemistry, Clinical Chemistry and Laboratory Medicine and the Journal of Molecular Diagnostics. He also serves on numerous corporate scientific advisory boards. He received his Ph.D. in Pathology from the University of Medicine and Dentistry of New Jersey and completed his postdoctoral training in molecular oncology and clinical chemistry/molecular pathology in the Department of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill.

Michael Frumkin
Michael has been an Engineering Director at Google since 2002 where his responsibilities have ranged from managing large engineering teams responsible for most of Google’s revenue, to overseeing critical internal software infrastructure projects.  Michael currently leads a Google Research team that he founded, whose primary aim is to bring Google’s expertise in machine intelligence and machine perception to bear on fundamental scientific research. 

Previously, Michael held several leadership roles at companies focused on large-scale computing and machine learning including being an advisor to Khosla Ventures, working primarily in the areas of data science and biology; CTO of Gamechange Inc., an early stage venture fund; Excite where he was responsible for web crawl and e-commerce engineering initiatives; NeXT where he worked on distributed computing systems; and Verity, a pioneering information retrieval company, where he was part of the core text retrieval group.  Michael graduated with SB and SM degrees in Computer Science and Engineering from MIT.  

Andrea Ferreira-Gonzalez, PhD

Andrea is the Chair of the Division of Molecular Diagnostics in the Department of Pathology at the Virginia Commonwealth University Health System. She is also the director of the Molecular Diagnostics Laboratory at the VCU Health System. 

Andrea is an internationally recognized expert in the field of molecular diagnostics in the area of genetics, oncology, personalized medicine, pharmacogenetics and infectious diseases in transplantation. In addition, she has played a major role in shaping national policy regarding the practice, reimbursement and guideline development for molecular diagnostics and molecular genetic testing. 

Andrea has also served as President of the Association for Molecular Pathology.  More recently, she served on the Department of Justice and National Institute of Standard and Technology National Commission on Forensic Sciences.  She was the recipient of the AMP Leadership Award for her major contributions to the field. She is a member of the Molecular Biology Education Committee for the International Federation of Clinical Chemistry (IFCC) where she has participated over the last 4 years in developing educational standards and hands on workshops on genetic testing for developing countries.

Andrea received her PhD degree from the George Washington University in Washington DC in 1994 and a master’s degree in Clinical Biochemistry from the National University of Cordoba, Argentina and she is board certified by the American Board of Bioanalysis as High Complexity Laboratory Director and Clinical Consultant.


Alex Dickinson, PhD, Founder and Executive Chairman
Alex is a life sciences executive with over 25 years experience leading strategic initiatives that have transformed small companies and enabled large companies to penetrate new markets.   Most recently, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems. Previously he led the team that built Illumina’s cloud-based sequencing informatics platform, BaseSpace, now the world’s largest genomic database. Alex joined Illumina in 2010 when the company acquired Helixis, a molecular diagnostics company that he led as CEO after co-founding with Caltech Professor Axel Scherer and Nobel Laureate David Baltimore. Alex was previously the founder and CEO of Luxtera, the leading provider of silicon photonic cloud infrastructure. He began his career as a researcher at AT&T Bell Labs and has been awarded over 40 patents covering a range of inventions including the camera and fingerprint CMOS chip technologies widely used in today’s smartphones. He holds a Ph.D. from the University of Adelaide, Australia, and an MBA from Columbia University in New York.

Jim Blair, PhD
Jim has been a partner of the venture capital firm Domain and Associates since the firm’s founding in 1985.  Jim has more than 40 years of experience with venture and emerging growth companies.  He has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano.  Other current board memberships include Applied Proteomics, Astute Medical, aTyr Pharma, Clovis Oncology, CoDa Therapeutics, IntegenX, and NeuroPace.   Jim also currently serves on the board of directors of the Prostate Cancer Foundation and the Sanford-Burnham Medical Research Institute and he is on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Caltech Division of Chemistry and Chemical Engineering.

Prior to Domain, Jim was a former managing director of Rothschild Inc., where he was directly involved at a senior level with Rothschild/New Court venture capital activities.  Previous to that, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies.  Jim was an engineering manager with RCA Corporation, during which time he received the David Sarnoff Fellowship.  He received his BSE from Princeton University and his MSE and Ph.D. in electrical engineering from the University of Pennsylvania.

Axel Scherer, PhD, Founder
Axel is a ChromaCode founder and the Bernard A. Neches Professor of Electrical Engineering, Applied Physics and Physics at Caltech.  He joined the Electrical Engineering department at Caltech in 1993, after working in the Microstructures Research Group at Bellcore.  Axel's group  works on micro- and nanofabrication of optical, magnetic and fluidic devices. He has co-authored over 300 publications and holds over 70 patents in the fields of optoelectronics, microfluidics, and new nanofabrication techniques. Axel has co-founded three high-technology companies and built a state of the art laboratory for advanced high-resolution lithography and pattern transfer at Caltech. He has pioneered microcavity lasers such as vertical cavity surface emitting lasers, microdisk lasers and photonic crystal lasers in many materials systems. Presently, his group works on integration of microfluidic chips with electronic, photonic and magnetic sensors. His group has also developed silicon nanophotonics and surface plasmon enhanced light emitting diodes, and has perfected the fabrication and characterization of ultra-small structures by lithography and electron microscopy. He received hi PhD in 1985 from the New Mexico Institute of Mining and Technology.

Gregory Gosch, President and CEO 



Unique skills and experiences enable us to successfully integrate life sciences and data sciences